https://www.selleckchem.com/pr....oducts/ly2606368.htm
Did a single entity emerge as 'the' Achilles heel of T1D? The arguments are summarized here, to make this case. To evaluate differences in end-of-life cost trajectories for cancer patients treated through Medicare versus by the Veterans Health Administration (VA). A retrospective analysis of VA and Medicare administrative data from FY 2010 to 2014. We employed three-level generalized estimating equations to evaluate monthly cost trajectories experienced by patients in their last year of life, with patients nested within hospital refer
Like
Comment
Share
